相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
KIT as a Therapeutic Target in Metastatic Melanoma
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non-Small-Cell Lung Cancer
Zengliu Su et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
E. F. Dunn et al.
ONCOGENE (2011)
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
D. Handolias et al.
BRITISH JOURNAL OF CANCER (2010)
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Hong Yang et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata et al.
EMBO MOLECULAR MEDICINE (2010)
Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors
R. Kefford et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212
J. R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Response to Imatinib Mesylate Depends on the Presence of the V559A-Mutated KIT Oncogene
Patrick Terheyden et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Jill C. Rubinstein et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma
Carmit Levy et al.
MOLECULAR CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Melanoma from bench to bedside: meeting report from the 6th international melanoma congress
D. E. Fisher et al.
Pigment Cell & Melanoma Research (2010)
Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma
J. Bauer et al.
BRITISH JOURNAL OF CANCER (2009)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Scott E. Woodman et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal et al.
PLOS ONE (2009)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2008)
Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation
Carolyn McGuinness et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Major response to imatinib mesylate in KIT-mutated melanoma
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Jose Lutzky et al.
PIGMENT CELL & MELANOMA RESEARCH (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
β-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development
Veronique Delmas et al.
GENES & DEVELOPMENT (2007)
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma
Cynthia Spittle et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition
Cristina R. Antonescu et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
Alastair J. King et al.
CANCER RESEARCH (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Determinants of BRAF mutations in primary melanomas
JL Maldonado et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development
W Zuidervaart et al.
BRITISH JOURNAL OF CANCER (2003)
Molecular genetic analysis of malignant melanomas for aberrations of the Wnt signaling pathway genes CTNNB1, APC, ICAT and BTRC
J Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Loss of membranous expression of β-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by Exon 3 mutations
A Demunter et al.
MODERN PATHOLOGY (2002)
Cytoplasmic and nuclear accumulation of β-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma
K Omholt et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
